ID

31715

Description

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT00741819

Lien

https://clinicaltrials.gov/show/NCT00741819

Mots-clés

Versions (1)
  1. 22/09/2018 22/09/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

22 septembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Pulmonary Arterial Hypertension NCT00741819

Anglais

Eligibility Pulmonary Arterial Hypertension NCT00741819

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
between 18 and 75 years of age
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
pah diagnosis defined by following who group i categories: idiopathic/familial, associated with unrepaired or repaired congenital systemic-to-pulmonary shunts (repaired >/= 5 years), associated with collagen vascular disease, associated with hiv, associated with appetite suppressant/toxin use
Description

Pulmonary arterial hypertension WHO classification | Idiopathic pulmonary arterial hypertension | Familial pulmonary arterial hypertension | Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunt | Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunt Repaired | Pulmonary arterial hypertension Associated with Collagen-vascular disease | Pulmonary arterial hypertension associated with HIV infection | Pulmonary arterial hypertension Associated with Appetite Depressants | Pulmonary arterial hypertension Associated with Use of Toxin

Type de données

boolean

Alias
UMLS CUI [1,1]
C2973725
UMLS CUI [1,2]
C4267671
UMLS CUI [2]
C3203102
UMLS CUI [3]
C1701939
UMLS CUI [4]
C3698160
UMLS CUI [5,1]
C3698160
UMLS CUI [5,2]
C0205340
UMLS CUI [6,1]
C2973725
UMLS CUI [6,2]
C0332281
UMLS CUI [6,3]
C0262428
UMLS CUI [7]
C3697673
UMLS CUI [8,1]
C2973725
UMLS CUI [8,2]
C0332281
UMLS CUI [8,3]
C0003620
UMLS CUI [9,1]
C2973725
UMLS CUI [9,2]
C0332281
UMLS CUI [9,3]
C1524063
UMLS CUI [9,4]
C0040549
baseline six-minute walk distance (6mwd) >/= 250 meters
Description

6-Minute Walk Test Meter Quantity

Type de données

boolean

Alias
UMLS CUI [1,1]
C0430515
UMLS CUI [1,2]
C0475209
UMLS CUI [1,3]
C1265611
currently receiving ventavis and be stable at current dose for 30 days prior to baseline
Description

Ventavis Dose Stable

Type de données

boolean

Alias
UMLS CUI [1,1]
C1541936
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
if currently receiving other approved background therapy (i.e. endothelin receptor antagonist or phosphodiesterase-5-inhibitor or both) must be on stable dose for 30 days prior to baseline
Description

Background Therapy Dose Stable | Endothelin receptor antagonist Dose Stable | Phosphodiesterase 5 inhibitor Dose Stable

Type de données

boolean

Alias
UMLS CUI [1,1]
C1706907
UMLS CUI [1,2]
C0087111
UMLS CUI [1,3]
C0178602
UMLS CUI [1,4]
C0205360
UMLS CUI [2,1]
C1134681
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
UMLS CUI [3,1]
C1318700
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C0205360
previous testing (e.g. right heart catheterization, echocardiography) consistent with diagnosis of pah
Description

Testing Consistent with Pulmonary arterial hypertension | Catheterization of right heart | Echocardiography

Type de données

boolean

Alias
UMLS CUI [1,1]
C0039593
UMLS CUI [1,2]
C0332290
UMLS CUI [1,3]
C2973725
UMLS CUI [2]
C0189896
UMLS CUI [3]
C0013516
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
nursing or pregnant
Description

Breast Feeding | Pregnancy

Type de données

boolean

Alias
UMLS CUI [1]
C0006147
UMLS CUI [2]
C0032961
has acute concomitant disease (e.g. portal hypertension, chronic thromboembolic disease, pulmonary veno-occlusive disease, etc) other than those accepted as part of the inclusion criteria or has had atrial septostomy
Description

Comorbidity Except Inclusion criteria | Hypertension, Portal | Thromboembolism chronic | Pulmonary Veno-Occlusive Disease | Atrial septostomy

Type de données

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0332300
UMLS CUI [1,3]
C1512693
UMLS CUI [2]
C0020541
UMLS CUI [3,1]
C0040038
UMLS CUI [3,2]
C0205191
UMLS CUI [4]
C0034091
UMLS CUI [5]
C0397233
history of uncontrolled sleep apnea, left-sided heart disease, or parenchymal lung disease
Description

Sleep Apnea Uncontrolled | Heart Disease Left sided Uncontrolled | Lung disease Parenchymal Uncontrolled

Type de données

boolean

Alias
UMLS CUI [1,1]
C0037315
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0018799
UMLS CUI [2,2]
C0443246
UMLS CUI [2,3]
C0205318
UMLS CUI [3,1]
C0024115
UMLS CUI [3,2]
C4277702
UMLS CUI [3,3]
C0205318
use of investigational drug within 30 days of baseline
Description

Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1]
C0013230
Retour au début de la page

Similar models

Eligibility Pulmonary Arterial Hypertension NCT00741819

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
between 18 and 75 years of age
boolean
C0001779 (UMLS CUI [1])
Pulmonary arterial hypertension WHO classification | Idiopathic pulmonary arterial hypertension | Familial pulmonary arterial hypertension | Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunt | Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunt Repaired | Pulmonary arterial hypertension Associated with Collagen-vascular disease | Pulmonary arterial hypertension associated with HIV infection | Pulmonary arterial hypertension Associated with Appetite Depressants | Pulmonary arterial hypertension Associated with Use of Toxin
Item
pah diagnosis defined by following who group i categories: idiopathic/familial, associated with unrepaired or repaired congenital systemic-to-pulmonary shunts (repaired >/= 5 years), associated with collagen vascular disease, associated with hiv, associated with appetite suppressant/toxin use
boolean
C2973725 (UMLS CUI [1,1])
C4267671 (UMLS CUI [1,2])
C3203102 (UMLS CUI [2])
C1701939 (UMLS CUI [3])
C3698160 (UMLS CUI [4])
C3698160 (UMLS CUI [5,1])
C0205340 (UMLS CUI [5,2])
C2973725 (UMLS CUI [6,1])
C0332281 (UMLS CUI [6,2])
C0262428 (UMLS CUI [6,3])
C3697673 (UMLS CUI [7])
C2973725 (UMLS CUI [8,1])
C0332281 (UMLS CUI [8,2])
C0003620 (UMLS CUI [8,3])
C2973725 (UMLS CUI [9,1])
C0332281 (UMLS CUI [9,2])
C1524063 (UMLS CUI [9,3])
C0040549 (UMLS CUI [9,4])
6-Minute Walk Test Meter Quantity
Item
baseline six-minute walk distance (6mwd) >/= 250 meters
boolean
C0430515 (UMLS CUI [1,1])
C0475209 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Ventavis Dose Stable
Item
currently receiving ventavis and be stable at current dose for 30 days prior to baseline
boolean
C1541936 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
Background Therapy Dose Stable | Endothelin receptor antagonist Dose Stable | Phosphodiesterase 5 inhibitor Dose Stable
Item
if currently receiving other approved background therapy (i.e. endothelin receptor antagonist or phosphodiesterase-5-inhibitor or both) must be on stable dose for 30 days prior to baseline
boolean
C1706907 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0205360 (UMLS CUI [1,4])
C1134681 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C1318700 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205360 (UMLS CUI [3,3])
Testing Consistent with Pulmonary arterial hypertension | Catheterization of right heart | Echocardiography
Item
previous testing (e.g. right heart catheterization, echocardiography) consistent with diagnosis of pah
boolean
C0039593 (UMLS CUI [1,1])
C0332290 (UMLS CUI [1,2])
C2973725 (UMLS CUI [1,3])
C0189896 (UMLS CUI [2])
C0013516 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Breast Feeding | Pregnancy
Item
nursing or pregnant
boolean
C0006147 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
Comorbidity Except Inclusion criteria | Hypertension, Portal | Thromboembolism chronic | Pulmonary Veno-Occlusive Disease | Atrial septostomy
Item
has acute concomitant disease (e.g. portal hypertension, chronic thromboembolic disease, pulmonary veno-occlusive disease, etc) other than those accepted as part of the inclusion criteria or has had atrial septostomy
boolean
C0009488 (UMLS CUI [1,1])
C0332300 (UMLS CUI [1,2])
C1512693 (UMLS CUI [1,3])
C0020541 (UMLS CUI [2])
C0040038 (UMLS CUI [3,1])
C0205191 (UMLS CUI [3,2])
C0034091 (UMLS CUI [4])
C0397233 (UMLS CUI [5])
Sleep Apnea Uncontrolled | Heart Disease Left sided Uncontrolled | Lung disease Parenchymal Uncontrolled
Item
history of uncontrolled sleep apnea, left-sided heart disease, or parenchymal lung disease
boolean
C0037315 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0018799 (UMLS CUI [2,1])
C0443246 (UMLS CUI [2,2])
C0205318 (UMLS CUI [2,3])
C0024115 (UMLS CUI [3,1])
C4277702 (UMLS CUI [3,2])
C0205318 (UMLS CUI [3,3])
Investigational New Drugs
Item
use of investigational drug within 30 days of baseline
boolean
C0013230 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial